UB Paderborn / Katalog / Suche / in CDI

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2012-01, Vol.30 (3), p.282-290

2012

Volltextzugriff (PDF)

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs

Drug metabolism and disposition, 2007-10, Vol.35 (10), p.1766

2007

Volltextzugriff (PDF)

Predicting Oral Clearance in Humans: How Close Can We Get with Allometry?

Clinical pharmacokinetics, 2008, Vol.47 (1), p.35-45

2008

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies

British journal of clinical pharmacology, 2014-09, Vol.78 (3), p.543-555

2014

Volltextzugriff (PDF)

The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools

Drug metabolism and disposition, 2007-04, Vol.35 (4), p.649

2007

Volltextzugriff (PDF)

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals

Clinical and translational science, 2022-05, Vol.15 (5), p.1196-1203

2022

Volltextzugriff (PDF)

Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers

The Journal of pharmacology and experimental therapeutics, 2005-05, Vol.313 (2), p.640

2005

Volltextzugriff (PDF)

Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation

Expert opinion on drug metabolism & toxicology, 2007-12, Vol.3 (6), p.865-878

2007

Volltextzugriff (PDF)

Effects of antibodies induced by a conjugate vaccine on 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone absorptive transport, metabolism, and proliferation of human lung cells

International journal of cancer, 2010-08, Vol.127 (3), p.513-520

2010

Volltextzugriff (PDF)

A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B

Clinical pharmacology and therapeutics, 2022-08, Vol.112 (2), p.372-381

2022

Volltextzugriff (PDF)

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

Blood, 2017-11, Vol.130 (21), p.2307-2316

2017

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

2020

Volltextzugriff (PDF)

Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay

Journal of computer-aided molecular design, 2009-12, Vol.23 (12), p.883-895

2009

Volltextzugriff (PDF)

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Clinical cancer research, 2014-04, Vol.20 (7), p.1935-1945

2014

Volltextzugriff (PDF)

Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry

Clinical pharmacokinetics, 2011-05, Vol.50 (5), p.307-318

2011

Volltextzugriff (PDF)

CYP3A but not P‐gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta‐specific phosphoinositide‐3 kinase inhibitor leniolisib

Biopharmaceutics & drug disposition, 2018-09, Vol.39 (8), p.394-402

2018

Volltextzugriff (PDF)

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Blood, 2018-11, Vol.132 (Supplement 1), p.3706-3706

2018

Volltextzugriff (PDF)

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S559-S560

2019

Volltextzugriff (PDF)

Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis?

Carcinogenesis (New York), 2005-04, Vol.26 (4), p.835-844

2005

Volltextzugriff (PDF)

Immunopropylactic approaches against chemical carcinogenesis

Vaccine, 2005-03, Vol.23 (17), p.2403-2406

2005

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications

Antimicrobial agents and chemotherapy, 2020-04

2020

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of BYL 719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies

British journal of clinical pharmacology, 2014-09, Vol.78 (3), p.543-555

2014

Volltextzugriff (PDF)

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3003-3003

2012

Volltextzugriff (PDF)

Perfluoroalkyl and polyfluoroalkyl substances in the environment: Terminology, classification, and origins

Integrated environmental assessment and management, 2011-10, Vol.7 (4), p.513-541

2011

Volltextzugriff (PDF)

Adding metabolic agents to prostate cancer therapy: Every rose has its thorn

European journal of cancer (1990), 2022-07, Vol.170, p.305-307

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs

Predicting Oral Clearance in Humans: How Close Can We Get with Allometry?

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies

The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals

Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers

Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation

Effects of antibodies induced by a conjugate vaccine on 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone absorptive transport, metabolism, and proliferation of human lung cells

A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications

Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry

CYP3A but not P‐gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta‐specific phosphoinositide‐3 kinase inhibitor leniolisib

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications

Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis?

Immunopropylactic approaches against chemical carcinogenesis

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications

Population pharmacokinetics and pharmacodynamics of BYL 719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors

Perfluoroalkyl and polyfluoroalkyl substances in the environment: Terminology, classification, and origins

Adding metabolic agents to prostate cancer therapy: Every rose has its thorn

Suchergebnisse filtern